Bristol-Myers Squibb

Bristol-Myers third-quarter net income up 4.2 percent to 721m dollars

Published: 08:09, October 24, 2014

New York City-based Bristol-Myers Squibb posted a third-quarter net income of $721 million (43 cents per share), which was 4.2% up on the $692 million (42 cents per share) in Q3 2013. The pharmaceutical giants’ figures topped most analysts’ estimates.

Revenue in the United States fell 3% to $2 billion, while international revenues declined by 4% in the third quarter.

Gross margin as a percentage of revenue was 74.3% compared to 71.1% in the same quarter last year.

Reported net earnings attributable to BMS came in at $721 million (43 cents per share) in the third quarter, versus $692 million (42 cents per share) in Q3 2013.

Focusing on cancer therapies

Bristol-Myers Squibb R&DBristol-Myers Squibb says its future is in cancer therapies (Photo: Bristol-Myers Squibb)

Over the last few years, Bristol-Myers Squibb (BMS) has been shifting its focus towards cancer medications that utilize the patient’s own immune system, such as melanoma drug Yervoy, which received FDA (Food and Drug Administration) approval three years ago.

Earlier this month, BMS announced it was abandoning its quest to gain FDA approval for its new hepatitis C combination medication.

Yervoy sales in Q3 2014 jumped to $350 million, an increase of 47% compared to the same quarter last year.

Rhematoid arthritis medication Orencia posted an 18% increased in sales to $444 million, Sprycel (leukemia medication) rose 22% to $385 million, while cardiovascular drug Eliquis registered sales of $216 million.

Opdivo received breakthrough designation from the FDA in September, meaning the melanoma medication will receive a faster review.

Non-small cell lung cancer medication Nivolumab has been validated by the European Medicine’s Agency for review for lung cancer and melanoma treatment.

Bristol-Myers Squibb’s CEO Lamberto Andreotti said:

“Our financial results in the third quarter reflect our continued focus on balancing long-term growth with short-term performance, as we achieved significant progress in our pipeline and saw strong in-market performance for key products including Eliquis, Yervoy, Sprycel and Orencia.”

“We continue to build a solid foundation for our future as a Diversified Specialty BioPharma by advancing our own R&D efforts and investing in strategic business development to build a sustainable pipeline.”

2014 Financial Guidance

BMS says it is adjusting its GAAP EPS guidance range from $1.50 – $1.60 to $1.15 – $1.25. It reiterated its non-GAAP EPS guidance range of $1.70 – $1.80. GAAP, or Generally Accepted Accounting Principles, are a set of official procedures, standards and rules that publicly-traded firms must comply with when preparing their financial statements.

Veronica Salvador Avatar

Other News

Personalized AI video ads drew more clicks in a WhatsApp experiment

Nov 19, 2026

Restaurant advertising results can depend on an existing reputation

Nov 19, 2026

Search suggestions can help shoppers find less familiar products

Nov 19, 2026

AI-generated shoppers can give misleading pricing estimates, study finds

Nov 19, 2026

The design of a discount label can change how shoppers judge an offer

Nov 19, 2026

What virtual shopping tools can change before and after a purchase

Nov 19, 2026

Game-like loyalty features drew more engagement in an online grocery study

Nov 18, 2026

A delivery cue helped more shoppers move to the next checkout step

Nov 18, 2026

Small changes in a store can bring promotions back to repeat customers’ attention

Nov 18, 2026

Some sellers accept less when a buyer shares an item’s heritage

Nov 18, 2026

Changing a marketplace trust badge can change what sellers prioritize

Nov 18, 2026

Referred customers may bring in more customers of their own

Nov 18, 2026

An extra option can make an attractive menu less appealing, experiments find

Nov 17, 2026

Adding similar choices can change which products look like the middle option

Nov 17, 2026

World Bank plans e-commerce pilot for small firms in three West African countries

Nov 17, 2026

Contextual ads were the most common targeting method among EU online advertisers

Nov 17, 2026

People treat the same money differently across spending categories, study finds

Nov 17, 2026

Small-business loan applications can stall before they are formally submitted

Nov 17, 2026

Describing the parts of an experience can change how much people enjoy it

Nov 16, 2026

A prize can feel different when customers know they might have received less

Nov 16, 2026